Overview

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant FSGS.
Phase:
Phase 1
Details
Lead Sponsor:
Northwell Health